Literature DB >> 27644332

Class II Phosphoinositide 3-Kinases as Novel Drug Targets.

Marco Falasca1, Justin R Hamilton2, Maria Selvadurai2, Krithika Sundaram3, Aleksandra Adamska1, Philip E Thompson3.   

Abstract

The phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases central to regulating a wide range of important intracellular processes. Despite the vast knowledge around class I PI3Ks, the class II PI3Ks have been neglected, seemingly only due to the chronology of their discovery. Here we focus on the cellular functions of the three class II PI3K isoforms, PI3KC2α, PI3KC2β, and PI3KC2γ, in different cell systems and underline the emerging importance of these enzymes in different physiological and pathological contexts. We provide an overview on the current development of class II PI3 kinase inhibitors and outline the potential use for such inhibitors. The field is in its infancy as compared to their class I counterparts. Nevertheless, recent advances in understanding the roles of class II PI3 kinases in different pathological contexts is leading to an increased interest in the development of specific inhibitors that can provide potential novel pharmacological tools.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27644332     DOI: 10.1021/acs.jmedchem.6b00963

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Cre/loxP approach-mediated downregulation of Pik3c3 inhibits the hypertrophic growth of renal proximal tubule cells.

Authors:  Ting Liu; Jialing Yuan; Caihong Dai; Jinxian Xu; Shude Li; Benjamin D Humphreys; Daniel T Kleven; Jian-Kang Chen
Journal:  J Cell Physiol       Date:  2020-05-31       Impact factor: 6.384

2.  Imidazopyridazine Inhibitors of PI3Kβ.

Authors:  Gerard Rosse
Journal:  ACS Med Chem Lett       Date:  2016-10-24       Impact factor: 4.345

3.  An Overview of Class II Phosphoinositide 3-Kinases.

Authors:  Emily Yan Zhi Heng; Tania Maffucci
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.737

Review 4.  Phosphoinositide 3-Kinases as Potential Targets for Thrombosis Prevention.

Authors:  Natasha M Setiabakti; Pia Larsson; Justin R Hamilton
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

5.  Identification of small molecule enzyme inhibitors as broad-spectrum anthelmintics.

Authors:  Rahul Tyagi; Mostafa A Elfawal; Scott A Wildman; Jon Helander; Christina A Bulman; Judy Sakanari; Bruce A Rosa; Paul J Brindley; James W Janetka; Raffi V Aroian; Makedonka Mitreva
Journal:  Sci Rep       Date:  2019-06-24       Impact factor: 4.379

Review 6.  PI3K inhibitors in thrombosis and cardiovascular disease.

Authors:  Tom N Durrant; Ingeborg Hers
Journal:  Clin Transl Med       Date:  2020-01-31

Review 7.  Phosphatidylinositol 3-monophosphate: A novel actor in thrombopoiesis and thrombosis.

Authors:  Colin Valet; Marie Levade; Marie Bellio; Manuella Caux; Bernard Payrastre; Sonia Severin
Journal:  Res Pract Thromb Haemost       Date:  2020-03-17

8.  Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growth.

Authors:  Ouma Cisse; Muzthahid Quraishi; Federico Gulluni; Federica Guffanti; Ioanna Mavrommati; Methushaa Suthanthirakumaran; Lara C R Oh; Jessica N Schlatter; Ambisha Sarvananthan; Massimo Broggini; Emilio Hirsch; Marco Falasca; Tania Maffucci
Journal:  J Exp Clin Cancer Res       Date:  2019-11-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.